Acute Stroke
Conditions
Keywords
acute stroke, cerebral infarction, neuroprotection
Brief summary
Evaluation of the efficacy and safety of Cytoflavin®, solution for intravenous administration, (OOO NTFF POLYSAN, Russia) for 10 days, patients with cerebral infarction who receive reperfusion therapy, with the start of treatment within the first 24 hours from the stroke onset, compared to treament with any other neuroprotective drug which may be used in routine clinical practice.
Interventions
DRUGCytoflavin (succinic acid + inosine + nicotinamide + riboflavin)
10 ml diluted to 100-200 ml of 5-10% dextroseor 0.9% sodium chloride solution. The rate of administration is 3-4 ml / min. The drug is administered in a volume of 10 ml per injection with an interval of 8-12 hours for 10 days. In severe cases of the disease, a single dose is increased to 20 ml.
DRUGControl
Standard treatment accordind to the routine clinical practice
Sponsors
POLYSAN Scientific & Technological Pharmaceutical Company
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Inclusion criteria
1. Signed Informed Consent; 2. Men and women 18-85 y.o.; 3. A diagnosis of cerebral infarction has been established and treatment with Cytoflavin® has already been prescribed, or other therapy has been prescribed that does not include Cytoflavin®; 4. NIHSS score of at least 5 and less than 24; 5. reperfusion therapy performed on admission; 6. The size of the ischemic focus according to ASPECTS score \>=6; 7. Time from stroke onset to admission not exceeeding 6 hours; 8. Start of therapy with Cytoflavin® within 24 hours from the onset of stroke (main group); 9. Patients who are able to follow the procedures of the Observational Study Program and strictly follow the doctor's instructions regarding drug therapy.
Exclusion criteria
1. Individual intolerance or known hypersensitivity to succinic acid, inosine, nicotinamide, riboflavin, or auxiliary components of the drug Cytoflavin®; 2. Hemorrhagic stroke; 3. Contraindications for CT scanning; 4. Initial severe disability requiring assistance in everyday life before stroke; 5. previous stroke with a residual neurological deficit; 6. Severe comorbidity with a life expectancy of less than 6 months; 7. Clinical or laboratory signs of an infectious disease on admission (with the exception of strokes that occurred in COVID-19 convalescents after the first 10 days of illness, and patients with asymptomatic SARS-CoV-2 infection detected during routine examination); 8. Pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with good functional outcome | 90 days | Proportion of patients who achieve score 0-2 by modified Rankin scale |
Countries
Russia
Outcome results
None listed